The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2024 | OCEAN study updates: HRQoL in patients with R/R myeloma treated with melflufen + dexamethasone
In this video, Fredrik Schjesvold, MD, PhD, Oslo Myeloma Center, Oslo, Norway, shares updates from the Phase III OCEAN study (NCT03151811), which compared melflufen plus dexamethasone versus pomalidomide plus dexamethasone in patients with relapsed/refractory (R/R) multiple myeloma. Dr Schjesvold gives an overview of the results of this study and further comments on the health-related quality of life (HRQoL) of patients enrolled in the trial. This interview took place at the 21st International Myeloma Society (IMS) Annual Meeting, held in Rio de Janeiro, Brazil.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
